Results of two Bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis

Annals of Surgery

Volumn 254, Issue 2, 2011, Pages 294-301

  Quenet, François ^a   Goéré, Diane ^b   Mehta, Sanket Sharad ^a   Roca, Lise ^a   Dumont, Fréderic ^b   Hessissen, Mehdi ^a   Saint Aubert, Bernard ^a   Elias, Dominique ^b  

^a CENTRE VAL D AURELLE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IRINOTECAN; OXALIPLATIN;

ADD ON THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CARDIOVASCULAR DISEASE; COLORECTAL CARCINOMA; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INTRA ABDOMINAL COMPLICATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; THERAPY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; NEOPLASM SEEDING; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; SECOND-LOOK SURGERY; TUMOR BURDEN; YOUNG ADULT;

EID: 79961044545     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182263933     Document Type: Article

References (36)

1. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550. (Pubitemid 35404323)
2. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364-367. (Pubitemid 19035034)
3. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284-3292. (Pubitemid 41103684)
4. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004;11(2):178-186. (Pubitemid 40486793)
5. Verwaal VJ, Van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-3743. (Pubitemid 46606227)
6. Verwaal VJ, Van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65-71. (Pubitemid 40486643)
7. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-68.
8. Elias D, Ouellet JF: Intraperitoneal chemohyperthermia: Rationale, technique, indications and results. Surg Oncol Clin North Am. 2001;10:915-933.
9. Ceelen WP, Hesse U, de Hemptinne B, et al: Review: hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg. 2000;87:1006-1015. (Pubitemid 30496848)
10. Elias D, Lefevre JH, Chevalier J, et al: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2008;27:681-685.
11. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/ folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13:58-65. (Pubitemid 43117646)
12. Ychou M, Viret F, Kramar A, et al: Tritherapy with fluorouracil/ leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Phamacol. 2008;62(2):195-201. (Pubitemid 351692073)
13. Rougier P, van Custem E, Bajetta E, et al. Randomized trial of irinotecan versus flourouracyl by continuous infusion after fluouracyl failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412. (Pubitemid 28510873)
14. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267-272. (Pubitemid 34704979)
15. Elias D, Matsuhisa T, Sideris L, et al: Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15:1558-1565. (Pubitemid 39409748)
16. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of the complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518-521. (Pubitemid 40486734)
17. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254-261. (Pubitemid 28146518)
18. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
19. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.
20. Elias D, Antoun A, Goharin A, et al. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest. 2000;1:431-439.
21. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181. (Pubitemid 36962641)
22. Quenet F, Claus C, Roca L, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from digestive tract cancer-New management with oxaliplatin plus irinotecan: a feasibility study in 37 patients. J Clin Oncol. 26:2008 (May 20 suppl; abstr 4084).
23. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-914.
24. Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly highdose infusional fluorouracil plus folinic acid with or without irinotecanin patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986. J Clin Oncol. 2005;23:4856-4865. (Pubitemid 46223990)
25. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947. (Pubitemid 30644117)
26. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
27. Falcone A, Ricci S, Brunetti l, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670-1676. (Pubitemid 46797946)
28. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
29. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342. (Pubitemid 38702844)
30. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229-237. (Pubitemid 41095086)
31. Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel and nonpseudomyxoma appendix. Ann Surg. 2010;251:896-901.
32. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863-869. (Pubitemid 40486849)
33. Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144-1153.
34. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635-644.
35. Elias D, Goere D, Blot F, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43°C after complete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14(6):1818-1824. (Pubitemid 46870938)
36. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22(7):1209-1214. (Pubitemid 41079833)